<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR44">
 <label>44.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Feldman</surname>
    <given-names>DR</given-names>
   </name>
   <name>
    <surname>Baum</surname>
    <given-names>MS</given-names>
   </name>
   <name>
    <surname>Ginsberg</surname>
    <given-names>MS</given-names>
   </name>
   <name>
    <surname>Hassoun</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Flombaum</surname>
    <given-names>CD</given-names>
   </name>
   <name>
    <surname>Velasco</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma</article-title>
  <source>J Clin Oncol</source>
  <year>2009</year>
  <volume>27</volume>
  <issue>9</issue>
  <fpage>1432</fpage>
  <lpage>1439</lpage>
  <pub-id pub-id-type="doi">10.1200/JCO.2008.19.0108</pub-id>
  <pub-id pub-id-type="pmid">19224847</pub-id>
 </element-citation>
</ref>
